According to Edwards Lifesciences's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 9.56905. At the end of 2023 the company had a P/S ratio of 7.70.
Year | P/S ratio | Change |
---|---|---|
2023 | 7.70 | -10.14% |
2022 | 8.57 | -44.56% |
2021 | 15.5 | 19.25% |
2020 | 13.0 | 15.54% |
2019 | 11.2 | 31.29% |
2018 | 8.55 | 23.08% |
2017 | 6.94 | 2.71% |
2016 | 6.76 | -0.91% |
2015 | 6.82 | 15.41% |
2014 | 5.91 | 68.23% |
2013 | 3.51 | -35.24% |
2012 | 5.43 | 12.92% |
2011 | 4.80 | -25.22% |
2010 | 6.42 | 72.1% |
2009 | 3.73 | 51.07% |
2008 | 2.47 | 3.59% |
2007 | 2.39 | -8.82% |
2006 | 2.62 | 5.42% |
2005 | 2.48 | -5.72% |
2004 | 2.63 | 26.62% |
2003 | 2.08 | -4.5% |
2002 | 2.18 | -8.09% |
2001 | 2.37 |
Company | P/S ratio | P/S ratio differencediff. | Country |
---|---|---|---|
Medtronic MDT | 3.58 | -62.58% | ๐ฎ๐ช Ireland |
Boston Scientific BSX | 7.08 | -25.98% | ๐บ๐ธ USA |
Merit Medical MMSI | 3.49 | -63.53% | ๐บ๐ธ USA |
LeMaitre Vascular LMAT | 7.66 | -19.94% | ๐บ๐ธ USA |
ICU Medical
ICUI | 1.15 | -88.01% | ๐บ๐ธ USA |
CryoLife CRY | N/A | N/A | ๐บ๐ธ USA |